Literature DB >> 12205190

Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.

Michael T Flink1, William D Atchison.   

Abstract

Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic disorder in which autoantibodies apparently target the voltage-gated Ca2+ channels that regulate acetylcholine (ACh) release at motor nerve terminals. P/Q-type Ca2+ channels are primarily involved in ACh release at mammalian neuromuscular junctions. Passive transfer of LEMS to mice by repeated administration of plasma from LEMS patients reduces the amplitude of the perineurial P/Q-type current, and unmasks a dihydropyridine (DHP)-sensitive L-type Ca2+ current at the motor nerve terminal. The present study sought to determine if this DHP-sensitive component contributes to ACh release. Mice were treated for 30 days with plasma from healthy human controls or patients with LEMS. For some studies, diaphragms from naive mice were incubated with LEMS or control human plasma for 2 or 24 h. End-plate potentials (EPPs) and miniature end-plate potentials (MEPPs) were recorded from neuromuscular junctions in the hemidiaphragm. Treatment of mice with LEMS plasma evoked the characteristic electrophysiological signs of LEMS: reduced quantal content and facilitation of EPP amplitudes at high-frequency stimulation. Quantal content was also reduced in muscles incubated acutely with LEMS plasma. Nimodipine, a DHP-type blocker of L-type Ca2+ channels, did not significantly affect the quantal content of muscles treated for 2 or 24 h with either control or LEMS plasma, or following chronic treatment with control plasma. However, following 30 days treatment with LEMS plasma, nimodipine significantly reduced the remaining quantal content to 57.7 +/- 3.3 % of pre-nimodipine control levels. Thus, DHP-sensitive Ca2+ channels become involved in synaptic transmission at the mouse neuromuscular junction after chronic, but not acute treatment with LEMS plasma. However, reductions in quantal release of ACh occur even after very short periods of exposure to LEMS plasma. As such, development of the L-type Ca2+ channel contribution to ACh release during passive transfer of LEMS appears to occur only after quantal release is significantly impaired for an extended duration, suggesting that an adaptive response of the ACh release apparatus occurs in LEMS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205190      PMCID: PMC2290502          DOI: 10.1113/jphysiol.2002.021048

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  57 in total

1.  Multiple types of calcium channels mediate transmitter release during functional recovery of botulinum toxin type A-poisoned mouse motor nerve terminals.

Authors:  M M Santafé; F J Urbano; M A Lanuza; O D Uchitel
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Abnormalities of autonomic function in the Lambert Eaton myasthenic syndrome.

Authors:  J P Heath; D J Ewing; R E Cull
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

3.  BAY K 8644 increases release of acetylcholine at the murine neuromuscular junction.

Authors:  W D Atchison; S M O'Leary
Journal:  Brain Res       Date:  1987-09-01       Impact factor: 3.252

4.  IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels.

Authors:  Y I Kim; E Neher
Journal:  Science       Date:  1988-01-22       Impact factor: 47.728

5.  Dihydropyridine-sensitive and -insensitive components of acetylcholine release from rat motor nerve terminals.

Authors:  W D Atchison
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

6.  Evidence for a dihydropyridine-sensitive and conotoxin-insensitive release of noradrenaline and uptake of calcium in adrenal chromaffin cells.

Authors:  P J Owen; D B Marriott; M R Boarder
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

7.  The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse.

Authors:  B Lang; J Newsom-Davis; C Peers; C Prior; D W Wray
Journal:  J Physiol       Date:  1987-09       Impact factor: 5.182

8.  The Lambert-Eaton myasthenic syndrome. A review of 50 cases.

Authors:  J H O'Neill; N M Murray; J Newsom-Davis
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

9.  Autonomic dysfunction in Lambert-Eaton myasthenic syndrome.

Authors:  R K Khurana; C L Koski; R F Mayer
Journal:  J Neurol Sci       Date:  1988-05       Impact factor: 3.181

10.  Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities.

Authors:  E H Lambert; V A Lennon
Journal:  Muscle Nerve       Date:  1988-11       Impact factor: 3.217

View more
  14 in total

1.  Upregulation of L-type calcium channels in colonic inhibitory motoneurons of P/Q-type calcium channel-deficient mice.

Authors:  Eileen Rodriguez-Tapia; Alberto Perez-Medina; Xiaochun Bian; James J Galligan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-01       Impact factor: 4.052

Review 2.  Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

Authors:  Stephen D Meriney; Tyler B Tarr; Kristine S Ojala; Man Wu; Yizhi Li; David Lacomis; Adolfo Garcia-Ocaña; Mary Liang; Guillermo Valdomir; Peter Wipf
Journal:  Ann N Y Acad Sci       Date:  2017-11-10       Impact factor: 5.691

3.  Age-dependent contribution of P/Q- and R-type Ca2+ channels to neuromuscular transmission in lethargic mice.

Authors:  Elizabeth Molina-Campos; Youfen Xu; William D Atchison
Journal:  J Pharmacol Exp Ther       Date:  2014-12-03       Impact factor: 4.030

Review 4.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

Review 5.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

6.  Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.

Authors:  Tyler B Tarr; David Lacomis; Stephen W Reddel; Mary Liang; Guillermo Valdomir; Michael Frasso; Peter Wipf; Stephen D Meriney
Journal:  J Physiol       Date:  2014-07-11       Impact factor: 5.182

Review 7.  Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.

Authors:  Tyler B Tarr; Peter Wipf; Stephen D Meriney
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

8.  Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice.

Authors:  Lingling Kong; Xueyong Wang; Dong W Choe; Michelle Polley; Barrington G Burnett; Marta Bosch-Marcé; John W Griffin; Mark M Rich; Charlotte J Sumner
Journal:  J Neurosci       Date:  2009-01-21       Impact factor: 6.167

9.  Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome.

Authors:  Tyler B Tarr; Waqas Malick; Mary Liang; Guillermo Valdomir; Michael Frasso; David Lacomis; Stephen W Reddel; Adolfo Garcia-Ocano; Peter Wipf; Stephen D Meriney
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

10.  Transmitter release site organization can predict synaptic function at the neuromuscular junction.

Authors:  Rozita Laghaei; Jun Ma; Tyler B Tarr; Anne E Homan; Lauren Kelly; Megha S Tilvawala; Blake S Vuocolo; Harini P Rajasekaran; Stephen D Meriney; Markus Dittrich
Journal:  J Neurophysiol       Date:  2017-12-27       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.